Biogen Inc. (FRA:IDP)

Market Cap	23.92B +17.5%
Revenue (ttm)	8.42B +2.2%
Net Income	1.10B -20.8%
EPS	7.49 -21.4%
Shares Out	n/a
PE Ratio	21.72
Forward PE	12.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30
Average Volume	31
Open	162.85
Previous Close	162.90
Day's Range	161.35 - 162.85
52-Week Range	99.82 - 169.30
Beta	n/a
RSI	57.91
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IDP

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD